| 20.73 0.14 (0.68%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.66 | 1-year : | 29.97 |
| Resists | First : | 21.96 | Second : | 25.66 |
| Pivot price | 20.54  |
|||
| Supports | First : | 19.79 |
Second : | 18.45 |
| MAs | MA(5) : | 20.45 |
MA(20) : | 20.4 |
| MA(100) : | 21.39  |
MA(250) : | 25.51 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 43 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 38 | Low : | 18.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SDGR ] has closed below upper band by 36.0%. Bollinger Bands are 65.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.86 - 20.93 | 20.93 - 21 |
| Low: | 19.97 - 20.07 | 20.07 - 20.15 |
| Close: | 20.58 - 20.71 | 20.71 - 20.83 |
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Tue, 10 Sep 2024
Schrödinger, Inc. (NASDAQ:SDGR) Stock Position Lifted by Bank of New York Mellon Corp - MarketBeat
Sun, 08 Sep 2024
Schrödinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wed, 28 Aug 2024
Schrödinger, Inc. (SDGR): Among The Best Medical AI Companies - Yahoo Finance
Wed, 31 Jul 2024
Schrödinger Reports Strong Second Quarter 2024 Financial Results - StockTitan
Fri, 26 Jul 2024
Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology - StockTitan
Wed, 12 Jun 2024
We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 64 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 95.6 (%) |
| Shares Short | 8,410 (K) |
| Shares Short P.Month | 8,200 (K) |
| EPS | -2.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.51 |
| Profit Margin | -100.5 % |
| Operating Margin | -111.5 % |
| Return on Assets (ttm) | -16.9 % |
| Return on Equity (ttm) | -37.2 % |
| Qtrly Rev. Growth | 34.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.15 |
| EBITDA (p.s.) | -3.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -180 (M) |
| Levered Free Cash Flow | -124 (M) |
| PE Ratio | -7.44 |
| PEG Ratio | 2 |
| Price to Book value | 3.18 |
| Price to Sales | 6.57 |
| Price to Cash Flow | -7.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|